{
  "id": 6970647,
  "title": "Ozempic, Wegovy enter Kenya as diabetes, obesity burden mounts",
  "url": "https://urgent.news/2026/09/12/ozempic-wegovy-enter-kenya-as-diabetes-obesity-burden-mounts",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-12T18:17:00.000Z",
  "source": {
    "name": "Capital FM Kenya",
    "slug": "capital-fm-kenya",
    "url": "https://capitalfm.africa/ozempic-wegovy-enter-kenya-as-diabetes-obesity-burden-mounts/"
  },
  "original_language": "en",
  "account": "NAIROBI, Kenya - Kenya has introduced two new prescription medicines, Ozempic and Wegovy, to address the growing burden of diabetes and obesity in the country. Both medicines contain semaglutide but serve different purposes and are prescribed at different doses. Ozempic is for managing type 2 diabetes while Wegovy focuses on weight management for those living with obesity or obesity-related health conditions. Novo Nordisk, the pharmaceutical company behind the medicines, officially launched them in Nairobi, acknowledging the increasing prevalence of type 2 diabetes in Africa, which has risen by over 142% in the past decade.\n\nExperts emphasize that the impact of these medicines will depend on patient affordability and early diagnosis. Consultant physician and endocrinologist Dr. Roseline Ngugi stressed that access to medicine alone won't reverse the trend, warning that many people with diabetes remain undiagnosed. She highlighted the need for greater investment in screening and early diagnosis, noting that obesity is not merely a lifestyle choice but a medical condition linked to cardiovascular and metabolic diseases, affecting people of all ages, including children.\n\nWhile the introduction of Ozempic and Wegovy provides additional treatment options, questions remain about their accessibility. Affordability and availability have historically posed challenges for treating chronic conditions. However, Novo Nordisk assures that the pricing for the medicines is affordable. Kenya's partnership with Denmark in healthcare and innovation may also play a role in addressing these health challenges.",
  "summary": "NAIROBI, Kenya, Sep 12— Kenya has expanded its treatment options for diabetes and obesity with the introduction of Ozempic and Wegovy, but experts say the impact of the new medicines…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "KBC",
        "title": "Ozempic, Wegovy introduced in Kenya as diabetes, obesity burden grows",
        "url": "https://urgent.news/2026/09/12/ozempic-wegovy-introduced-in-kenya-as-diabetes-obesity-burden-grows",
        "published": "2026-09-12T17:17:13.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}